DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c54813) has announced the addition of “Eisai Prospects to 2011″ to their offering.
Eisai sells products within the following therapeutic areas: neurology; gastroenterology; cardiovascular and respiratory; anti-infectives; metabolic and diagnostics. It is now focusing its research and development efforts on neurology, gastroenterology and oncology/critical care.
Current Growth Drivers
Related Results
With Meridia, Weight Drops, But Not Blood Pressure
BASF May Favor Life Sciences At the Expense of Pharmaceuticals.
Sibutramine metaanalysis.(CLINICAL CAPSULES)(Brief Article)
Combined-therapy program helps obese patients lose more weight.(Adult Psychia…
Sibutramine improves obesity factors in teens.(Clinical Rounds)
Aricept, a selective acetylcholinesterase inhibitor for the treatment for Alzheimer’s disease (AD), is a hugely significant product for Eisai, sales have shown impressive growth year-on-year since its launch in 1997. It is now the company’s top selling prescription drug and benefits from co-promotion in many markets with the pharmaceutical giant, Pfizer. Aricept is currently being developed for eight new indications/formulations in a range of important markets.
Along with Aricept, Aciphex is one of the company’s key products. Since its launch in Japan, the drug has gone on to achieve approvals and launches in more than 72 countries worldwide. In many of these markets the drug benefits from co-promotional activities with Janssen (Johnson & Johnson) and sales continue to show significant year-on-year growth.
Key Late-Phase Products Reaching the Market Place
Eisai is co-developing Abbott’s adalimumab (marketed as Humira) for markets in Japan, Thailand and Korea. Currently it is one of Abbott’s highest selling products and Eisai hope to emulate this success in Japan. It is currently awaiting approval for the treatment of rheumatoid arthritis.
Key Late-Stage Products
Eisai is optimistic about filing KES524 (sibutramine), by fiscal 2008. It is in Phase III trials in Japan for the treatment of obesity. With an estimated market potential for Japan of about $150 million ([yen]17.4 billion), it could become Eisai’s leading metabolic drug.
Areas covered:
- Latest Results
- Executive Summary
- Financial Analysis (current year)
- Company Strategy
- Product/R&D Pipeline
- Appendices
- 5-year financial assessment
- Key corporate events
- Key agreements
- Infrastructure
- Major pharmaceutical subsidiaries/joint ventures
- Product index.
For more information visit http://www. evista. researchandmarkets.com/reports/c54813
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning